PRESS RELEASEMay 6, 2015

Removal of Ovaries Associated with Decrease in Breast Cancer Death in Women with Breast Cancer and BRCA1 Mutation

  • May 6, 2015

April 23, 2015  |  Download Release

Removal of the ovaries, a procedure known as an oophorectomy, was associated with a 62 percent reduction in breast cancer death in women diagnosed with breast cancer and carrying a BRCA1 gene mutation, according to an article published online by JAMA Oncology.

Women who carry a germline mutation in either the BRCA1 or BRCA2 gene face a lifetime risk of breast cancer of up to 70 percent. Once they are diagnosed with breast cancer, they face high risks of both second primary breast and ovarian cancers. Other studies of BRCA gene mutation carriers have reported reduced mortality associated with oophorectomy for women with a history of breast cancer, according to the study background.

Steven A. Narod, M.D., and Kelly Metcalfe, Ph.D., of the Women’s College Research Institute, Toronto, Canada, and coauthors sought to confirm these earlier observations in a group of women with BRCA1 and BRCA2 gene mutations and early-stage breast cancer. Their study included 676 women, of whom 345 underwent oophorectomy after being diagnosed with breast cancer, while 331 women retained both ovaries.

The study found 20-year survival for the entire group was 77.4 percent. In the entire group, there was a 56 percent reduction in breast cancer death associated with oophorectomy. Undergoing an oophorectomy was associated with a significant reduction (62 percent) in breast cancer death in women with a BRCA1 mutation but not in women with a BRCA2 mutation because the 43 percent reduction authors found was not statistically significant.

In addition there were nine deaths from ovarian cancer in the group of women who did not have oophorectomies. The authors found a 65 percent reduction in all-cause mortality associated with oophorectomy in their analysis.

According to the study results, oophorectomies were performed an average of six years after breast cancer diagnosis. For the 70 BRCA1 carriers for whom the oophorectomy was performed within two years of breast cancer diagnosis, there was a 73 percent reduction in death compared with women with a BRCA1 mutation who never underwent oophorectomy. The authors note the protective effect of oophorectomy on deaths from breast cancer was apparent immediately after diagnosis and lasted for 15 years.

“It is important that follow-up studies be performed on women who undergo oophorectomy as part of their initial treatment, in particular, those women who undergo oophorectomy in the first year after diagnosis. It is also important that our observations be confirmed in other study populations. Further data are needed, in particular for BRCA2 carriers in order to confirm the benefit of oophorectomy in this population,” article concludes.

Editor’s Note: This research was funded by the Canadian Breast Cancer Foundation and an author made a funding/support disclosure. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #

This release was prepared by JAMA Network Media Relations.
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org .

About

Women’s College Hospital

For more than 100 years Women’s College Hospital (WCH) has been developing revolutionary advances in healthcare. Today, WCH is a world leader in the health of women and Canada’s leading, academic ambulatory hospital. A champion of health equity, WCH advocates for the health of all women from diverse cultures and backgrounds and ensures their needs are reflected in the care they receive. It focuses on delivering innovative solutions that address Canada’s most pressing issues related to population health, patient experience and system costs. The WCH Institute for Health System Solutions and Virtual Care (WIHV) is developing new, scalable models of care that deliver improved outcomes for patients and sustainable solutions for the health system as a whole.

Women’s College Research Institute (WCRI) is tackling some of the greatest health challenges of our time. Its scientists are conducting global research that advances the health of women and improves healthcare options for all, and are then translating those discoveries to provide much-needed improvements in healthcare worldwide.

For more information about how WCH and WCRI are transforming patient care, visit www.womenscollegehospital.ca and www.womensresearch.ca

Fully affiliated with

A member of